Teckro Logo

February 25, 2022

Our Bold Goal for the Pancreatic Cancer Survival Rate - Cassadie Moravek

Cassadie Moravek

Cassadie Moravek

Senior Director, Clinical Trial Portfolio and Program Management at Pancreatic Cancer Action Network

Guest
 

Pancreatic cancer is one of the deadliest forms of cancer. With a five-year survival rate of just 11%, a diagnosis has long been considered a death sentence.

However, there is hope. Cassadie Moravek, a director of clinical trial operations at the Pancreatic Cancer Action Network, joins us to explain how genetic testing and biomarkers are changing the game for patients – and elaborates on ambitious plans to increase the survival rate to 20% by 2030.

"So many people don't realize the options available to them, even though genetic testing has made huge leaps forward in the last few years."